BPC-157 10 mg

Compound profile

BPC-157: compound profile, literature landscape and handling notes

Where BPC-157 came from

BPC-157 entered the literature in the 1990s from a Zagreb-based gastroenterology group working in the cytoprotection tradition, a line of research concerned with agents that preserve gastric mucosal integrity by something other than acid suppression. The peptide was described as a partial sequence of a larger protein that the same line of work reported isolating from human gastric juice and named body protection compound. The fifteen-residue fragment taken from that sequence was designated BPC-157, and essentially the entire literature that followed concerns the fragment rather than the parent.

That origin story appears on almost every page ever written about this compound, so it is worth being exact about what it establishes. The pentadecapeptide is a synthetic construct assembled by solid-phase synthesis. It has never been isolated from tissue as an endogenous fifteen-residue species, and there is no published account of a protease that liberates it in vivo. All of the naturalness in the phrase sits with the parent protein, and the parent protein is the part of the story that is least developed: it does not carry the accession record, structural characterization, expression profiling and independent re-isolation history that a well-established human protein accumulates over time. Reduced to its evidentiary content, the claim is that one group reported a protein, reported part of its sequence, and synthesized that part. The framing derived from a naturally occurring protein is therefore weaker than it sounds, and a research buyer should treat the peptide as what it demonstrably is, a designed synthetic sequence with an interesting provenance narrative attached.

None of that makes the molecule uninteresting; plenty of useful tool compounds are synthetic fragments with thin natural pedigrees. It does mean the naturalness argument should carry no weight in an experimental rationale. It is also worth noting what is absent from the origin record: no regulatory approval in any jurisdiction, and although review articles from the originating line of work refer to early clinical exploration, the corresponding controlled data are not present in the peer-reviewed record in a form an outside reader can evaluate.

Reading the structure of BPC-157

The sequence, formula and mass for this listing are printed in the specification table further down this page. What is worth saying here is what is absent from that string, because in this case the absences are more informative than the residues. There are no cysteines and therefore no disulfide bonds and no folding step. There are no non-proteinogenic or D-configured residues. There is no fatty-acid conjugation and no C-terminal amidation; the C-terminus is a free acid. BPC-157 is, structurally, an ordinary unmodified linear peptide, and every one of the design motifs that dominate the acylated analogs elsewhere in this catalog is simply not present.

That has direct consequences on the bench. Synthesis is standard Fmoc solid-phase chemistry with no conjugation step, no oxidative folding, and no chromatographic separation of disulfide isomers, which is the main reason material at this length is inexpensive and widely available. The failure modes are correspondingly ordinary: deletion sequences from incomplete coupling, truncations, and the aggregation-on-resin problems that a run of consecutive prolines is well known to cause. Those are the impurities to think about, not misplaced lipid chains.

Material of this class is normally supplied as an acetate salt. That matters for two reasons. The labeled mass in a vial is peptide plus counterion plus residual water, so gross mass and net peptide content are not the same number, and the gap is larger for a short peptide than for a large one. Second, acetate is the preferred counterion precisely because the trifluoroacetate left over from reversed-phase purification is itself active in some cell assays, so a lot that has not been salt-exchanged can produce readouts that have nothing to do with the peptide.

The claim that BPC-157 is stable in gastric juice deserves care, because it is repeated constantly and its logic is often garbled. Stability in an acidic proteolytic environment is a claim about the molecule: that it resists acid-catalyzed hydrolysis and pepsin cleavage under defined conditions for a defined interval. A short peptide with no acid-labile modifications and a proline-rich backbone is a plausible candidate for above-average resistance, and plausible is the right word, because the claim is asserted far more often than it is independently measured, and the conditions under which any measurement was made are rarely stated alongside the assertion. It is also routinely slid into a second and much larger claim, that the intact molecule crosses an epithelium. Those are separate questions and the first does not answer the second.

The target and the pathway in more detail

There is no confirmed receptor for BPC-157. That is the single most important fact about its pharmacology and it belongs at the front of any honest description. No binding partner has been identified, no saturable binding site has been characterized, there is no published radioligand binding curve, and there is no genetic model in which deleting a candidate receptor abolishes a reported effect. Every mechanistic proposal in the literature is inferred from downstream pathway readouts in tissue or cells that were exposed to the peptide, which is a categorically weaker form of evidence than a binding target.

The proposal with the most published support concerns the nitric oxide system. A recurring experimental design pairs the peptide with a nitric oxide synthase inhibitor and with an arginine substrate load and reports that the direction or magnitude of an effect shifts. That design can establish that an effect is sensitive to nitric oxide availability. It cannot establish where in the pathway the peptide acts, and it does not distinguish a direct interaction from a consequence of some upstream event.

A second cluster of reports centers on angiogenesis, and specifically on vascular endothelial growth factor receptor 2. Increased VEGFR2 expression, receptor internalization and downstream activation of endothelial nitric oxide synthase have been described in endothelial preparations, which is a coherent story because it links the angiogenic readouts in the injury models back to the nitric oxide thread. A third cluster concerns growth-factor and adhesion signaling: reported changes in early growth response 1 and its corepressor, and in focal adhesion kinase and paxillin, which are the canonical readouts for cell adhesion, spreading and migration in fibroblast and tendon-cell work. A fourth, largely separate cluster comes from rodent behavioral pharmacology, where the peptide has been reported to modify responses to dopaminergic and serotonergic challenge agents.

Each of these is best described as proposed and partially supported. The common weakness is structural rather than technical: a pathway readout tells you that something moved, and in an injured tissue a great many things move for a great many reasons, including nonspecific stress responses and differences in the extent of the initial injury. Until a binding target exists, statements of the form BPC-157 acts through the nitric oxide pathway should be read as shorthand for its reported effects are sensitive to manipulation of that pathway, which is a much narrower claim.

What the published literature on BPC-157 actually measures

The published BPC-157 record is unusual in shape, and the shape matters more than the page count. It is overwhelmingly rodent, overwhelmingly acute-injury, and overwhelmingly produced by one line of research.

The models recur with very little variation: transected or otherwise damaged Achilles tendon and ligament, crushed skeletal muscle, chemically or mechanically induced gastric and colonic lesions, transected or compressed sciatic nerve, various vascular occlusion preparations, fistula healing, and toxicity challenges with agents such as nonsteroidal anti-inflammatory compounds or alcohol. The readouts are equally consistent: macroscopic lesion scoring, semi-quantitative histology, load-to-failure and other biomechanical measures for tendon, and functional indices such as walking-track scoring for nerve. Many of these endpoints are ordinal scores assigned by an observer, which makes blinding and prespecified scoring criteria central to their interpretation, and those methodological details are stated less often than a reader would want.

The provenance is the part that cannot be left out of any fair summary. A very large proportion of the corpus originates from a single group in Zagreb and its immediate collaborators, spanning decades and covering most of the model systems above. Independent replication by unrelated laboratories exists but is limited, and it is concentrated in the in vitro end of the range, tendon and fibroblast culture work on migration, proliferation and collagen expression, rather than in the injury models where the strongest claims are made. When one group generates most of a literature, the reported effects share not only authorship but methodology, scoring conventions, animal sourcing and reagent supply, so agreement across those papers is much less independent evidence than the same number of papers from different laboratories would be.

There is essentially no controlled human data in the peer-reviewed record. That is not a statement that the compound has been tested and failed; it is a statement that the evaluable record is absent. Secondary sources fill that vacuum with material that is not literature at all: conference abstracts, review articles from the originating group that cite unpublished work, vendor pages, and self-reported accounts. Anyone building a citation list for this compound should sort the references by who generated them and by whether the study is in vivo rodent, in vitro, or neither, before drawing any conclusion about weight of evidence.

Where the BPC-157 literature is thin or frequently misread

If you read only one section on this compound, this should be it, because the failure modes here are systematic rather than incidental.

The first is the single-group concentration problem. A corpus dominated by one laboratory shares more than authorship. It shares experimental design conventions, scoring rubrics, animal strain and supplier, peptide sourcing, and the analytical assumptions behind the material used. A systematic error anywhere in that chain propagates through every paper without ever producing a disagreement that would expose it. This is not an accusation of anything; it is a structural property of how the evidence was generated, and it means the effective number of independent observations is far smaller than the number of publications suggests.

The second is the missing receptor. Compounds without an identified molecular target are not automatically suspect, but they are much harder to falsify, because there is no binding assay to fail and no knockout to be negative. The mechanistic literature consists of pathway readouts, and pathway readouts in injured tissue are exactly the kind of measurement that moves for reasons unrelated to the compound under test.

The third is over-extrapolation from rodent injury models. A transected rodent tendon healing faster under an experimental condition is a finding about that model. Rodent connective tissue healing kinetics, gastrointestinal physiology and injury response differ substantially from human equivalents, and the secondary literature routinely drops the qualifier entirely, converting a model result into a general claim about repair.

The fourth is chemical: BPC-157 arginate and stable BPC-157 are marketing designations, not characterized chemical entities. There is no published comparative characterization establishing that an arginate salt of this peptide is a distinct species with different stability, and no peer-reviewed head-to-head data against the acetate form. A counterion change is a real chemical difference in principle, but until someone publishes comparative degradation kinetics under stated conditions, the designation carries no evidentiary content and should not be treated as a grade.

The fifth is the general reproducibility question that follows from all of the above. The appropriate response is not to discard the literature but to design internally controlled experiments: vehicle and positive comparator arms in the same run, blinded scoring, prespecified endpoints, and analytical confirmation of the material actually used. The single most common error made with this compound is treating volume of publication as if it were weight of evidence.

How BPC-157 behaves in solution

Relative to the acylated peptides elsewhere in this catalog, BPC-157 is well behaved in solution, and the reason is structural. With no lipid tail there is no surfactant character, no concentration-dependent self-association driven by a hydrophobic chain, and no albumin-binding behavior to complicate a matrix. The peptide is freely soluble in water and in the usual aqueous buffers, and it does not require an organic co-solvent or a pH excursion to bring it into solution. That removes most of the handling hazards that dominate the amphiphilic analogs.

It does not remove all of them. Every peptide adsorbs to surfaces to some degree, and the loss is worst where it is least visible, at low concentration in a large-surface-area container. Low-binding labware, minimal headspace and a minimal number of transfer steps remain sensible even for an undemanding molecule. Repeated freeze-thaw cycling is less catastrophic here than for an aggregation-prone amphiphile, but ice formation still concentrates solutes at the freezing front and still produces cumulative loss, so single-use aliquots at a working concentration remain the right pattern.

The chemistry to watch is aspartate. Short peptides containing aspartate residues undergo isomerization through a cyclic succinimide intermediate, giving isoaspartate and, along the way, opportunities for backbone cleavage. The rate depends strongly on pH and temperature, with the acid-catalyzed and base-catalyzed routes having different products and different neighboring-residue dependencies. What makes this the important degradation route for this particular peptide is that isoaspartate formation is mass-silent: the isomer has the same molecular formula as the parent, so it is invisible to any identity check that consists of a single measured mass.

There is a practical corollary about appearance. This peptide has no aromatic residues and no metal center, so a degraded solution generally looks exactly like an intact one, clear and colorless, with no yellowing, no opalescence and no visible precipitate until something has gone very wrong indeed. Absence of visible change is not evidence of integrity. Conversely, cloudiness in an aqueous peptide solution held at room temperature should be treated as a microbial question first, since a peptide solution in unpreserved water is a perfectly good growth medium.

Analytical notes specific to BPC-157

Two features of this molecule make its analytical record read differently from that of a large modified peptide, and both cut against the reader.

The first is mass. At fifteen residues the molecular mass is low enough that identity by mass alone is weakly discriminating. Enormous numbers of fifteen-residue sequences, and a great many synthesis-derived impurities, land within a narrow window of any given value, and residue substitutions that swap one amino acid for another of similar mass are common. For a large distinctive molecule an accurate mass constrains the composition tightly; here it does much less work. That is why tandem mass spectrometry with an interpretable fragment ion series, confirming the actual residue order rather than only the total, is more informative for this compound than for almost anything else in the catalog. It is also the only routine method that will distinguish a correct sequence from a transposition of two residues.

The second is detection. The peptide contains no tryptophan, tyrosine or phenylalanine, so it has essentially no absorbance at 280 nm and cannot be quantified there at all. Reversed-phase detection relies on the amide bond in the low ultraviolet, typically around 214 nm, where the response scales roughly with the number of peptide bonds. That introduces a systematic bias into area-percent purity: short truncation and deletion impurities absorb less per mole than the full-length peptide, so their contribution is understated relative to their true molar abundance. A purity figure from this method is a real measurement but not a molar one.

A single sharp peak is therefore worth interpreting carefully. It is good evidence of good chromatography and it does exclude grossly different species, but it does not exclude co-eluting isobaric forms such as isoaspartate variants or residues that racemized during synthesis, and it does not exclude anything that fails to absorb or ionize. Two further points are specific to this sequence. Its multiple prolines undergo cis-trans isomerization on a timescale comparable to chromatographic separation, which can broaden or split a peak without any impurity being present, so peak shape should be read against a method that is known to behave. And purity, identity and content are three different measurements: net peptide content, meaning how much of the labeled mass is peptide rather than acetate and water, is the one most often missing from supplied paperwork and the one that most directly changes a calculated concentration.

Compounds researchers confuse with BPC-157

Questions specific to BPC-157